Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are focused on treating respiratory diseases with significant unmet need, such as COPD, cystic fibrosis and asthma.
Our technology was developed and spun out of Dr. John Fahy’s airway biology lab at University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson’s glycochemistry lab at University College Dublin and Dr. Anne Marie Healy’s pharmaceutics lab at Trinity College Dublin. The efforts of this research consortium led to over $18M in NIH grant funding, resulting in the identification of our lead therapeutic candidate (AER-01), establishment of preliminary safety and efficacy profiles, and the production of clinical trial API.
Our technology was developed and spun out of Dr. John Fahy’s airway biology lab at University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson’s glycochemistry lab at University College Dublin and Dr. Anne Marie Healy’s pharmaceutics lab at Trinity College Dublin. The efforts of this research consortium led to over $18M in NIH grant funding, resulting in the identification of our lead therapeutic candidate (AER-01), establishment of preliminary safety and efficacy profiles, and the production of clinical trial API.
Location: United States, California, San Francisco
Employees: 1-10
Total raised: $51.88M
Founded date: 2014
Investors 2
| Date | Name | Website |
| 30.08.2023 | OrbiMed | orbimed.co... |
| 10.07.2026 | Canaan Par... | canaan.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.04.2023 | Series A | $36M | - |
| 22.12.2022 | - | $15.88M | - |
Mentions in press and media 8
| Date | Title | Description |
| 22.04.2023 | BioSpace: Aer Therapeutics Raises $36M for Novel Approach to COPD | - |
| 14.04.2023 | Aer Therapeutics bags €32.7M to develop treatment for mucus-associated lung diseases: Know more | Aer Therapeutics, a biopharmaceutical spin-out company and a collaboration between University College Dublin (UCD) and the University of California, San Francisco (UCSF), announced on Friday that it has secured $36M (approximately €32.7M) i... |
| 14.04.2023 | UCD spin-out Aer Therapeutics closes $36m funding round | Aer Therapeutics, a UCD biopharma spin-out developing inhaled treatments for lung diseases has closed a $36m Series A financing round led by leading science investors including Canaan, OrbiMed, and Hatteras Venture Partners. The funding wil... |
| 14.04.2023 | Aer Therapeutics Raises $36M in Series A Funding | Aer Therapeutics Logo Aer Therapeutics, a Raleigh, North Carolina-based biopharmaceutical company developing novel inhaled treatments for muco-obstructive lung diseases, raised $36M in Series A funding. Backers included Canaan, OrbiMed, and... |
| 13.04.2023 | Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases | - |
| 13.04.2023 | Aer Therapeutics Inks $36M Series A Round | RALEIGH, N.C., Aer Therapeutics, a biopharmaceutical company developing novel inhaled treatments for muco-obstructive lung diseases, has announced the closing of a $36 million Series A financing. >> Click here for more funding data... |
| - | Biopharmaceutical Company Aer Therapeutics Raises $36 Million In Series A Funding | Aer Therapeutics – a biopharmaceutical company developing novel inhaled treatments for muco-obstructive lung diseases – announced the closing of a $36 million Series A financing. The funding was received from a syndicate of premier life sci... |
| - | Aer Therapeutics | - |